血红蛋白-白蛋白-淋巴细胞-血小板评分与B型利钠肽对择期体外循环冠脉搭桥术后30天死亡率的增量预后价值
本研究纳入466例有完整数据的择期体外循环冠状动脉旁路移植术(CABG)患者,评估术前血红蛋白-白蛋白-淋巴细胞-血小板(HALP)评分和B型利钠肽(BNP)与术后30天死亡率的关联。
要点
- 低HALP和高BNP是择期体外循环CABG术后30天死亡的独立相关因素。
- 在EuroSCORE II基础上加入HALP和BNP可改善预后判别能力。
- 研究结果属探索性,需进一步验证。
核心结论
- 较低的HALP评分和较高的BNP与择期体外循环CABG术后30天死亡率相关,并可能提供超越EuroSCORE II的增量预后信息。
研究设计与样本
- 研究纳入492例符合条件的患者,其中466例具有30天死亡率和预设主要预测因子完整数据的患者构成主要分析队列。
- 采用Firth惩罚逻辑回归分析关联,并通过bootstrap重采样进行内部验证。
主要发现
- 在调整EuroSCORE II后,较低的HALP和较高的BNP仍独立与死亡率相关。
- 乐观校正后的曲线下面积从EuroSCORE II单独使用的0.879提高到加入HALP后的0.974,进一步加入BNP后提高到0.979。
临床怎么用
- 对于择期体外循环CABG患者,可考虑术前检测HALP评分和BNP以辅助风险评估。
- HALP和BNP可能作为EuroSCORE II的补充指标,但当前证据为探索性,尚不能替代现有评估工具。
局限性
- 研究结果应被视为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study evaluated whether preoperative haemoglobin-albumin-lymphocyte-platelet (HALP) score and B-type natriuretic peptide (BNP) were associated with 30-day mortality after elective on-pump coronary artery bypass grafting (CABG) and whether they improved prognostic assessment beyond European System for Cardiac Operative Risk Evaluation II (EuroSCORE II). METHODS: Among 492 eligible patients, 466 with complete data on 30-day mortality and the prespecified primary predictors constituted the primary analytic cohort. Associations were examined using Firth penalized logistic regression, and internal validation was performed with bootstrap resampling. RESULTS: Twenty-one patients (4.5%) died within 30 days. Lower HALP and higher BNP were independently associated with mortality after adjustment for EuroSCORE II. The optimism-corrected area under the curve improved from 0.879 for EuroSCORE II alone to 0.974 after the addition of HALP and to 0.979 after further addition of BNP. CONCLUSIONS: Lower HALP and higher BNP were associated with 30-day mortality after elective on-pump CABG and may provide incremental prognostic information beyond EuroSCORE II. These findings should be considered exploratory.
引用
- Yalınız H, Benli O. Incremental Prognostic Value of the Haemoglobin-Albumin-Lymphocyte-Platelet Score and B-Type Natriuretic Peptide for 30-Day Mortality After Elective On-Pump Coronary Artery Bypass Grafting. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42378454. doi:10.1093/icvts/ivag190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。